ciprofloxacin has been researched along with Sinusitis in 17 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Sinusitis: Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a prospective, randomized, double-blind pilot study of oral ciprofloxacin (500 mg twice daily) versus cefuroxime axetil (250 mg twice daily) for 2 to 3 weeks in the treatment of adult patients with a clinical diagnosis of acute bacterial maxillary sinus infections or acute exacerbation of chronic bacterial sinusitis." | 9.08 | Ciprofloxacin versus cefuroxime axetil in the treatment of adult patients with acute bacterial sinusitis. ( Echols, RM; Heyd, A; Klein, GL; Whalen, E, 1998) |
| "A total of 251 adults with chronic sinusitis were enrolled into this prospective multicentre, double-blind, double-placebo comparison of ciprofloxacin (500 mg twice daily) with amoxycillin/clavulanic acid (500 mg three times daily)." | 9.07 | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| "80 adult outpatients suffering from otitis media, sinusitis (maxillaris or frontalis) or peritonsillitis were treated with 500 mg ciprofloxacin b." | 9.06 | Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V--a comparison. ( Falser, N; Mittermayer, H; Weuta, H, 1988) |
| "Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)." | 8.85 | Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. ( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009) |
| "To test whether intranasal ciprofloxacin/dexamethasone or dexamethasone alone affects the course of acute bacterial rhinosinusitis in mice." | 7.74 | Effect of topical ciprofloxacin/dexamethasone or dexamethasone alone on acute Streptococcus pneumoniae rhinosinusitis in mice. ( Baroody, F; Markaryan, A; Naclerio, R; Sahin-Yilmaz, A; Thompson, K; Wall, GM, 2008) |
| " Ten adverse events were observed in seven patients and in four (7%) of these treatment had to be withdrawn." | 6.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "We conducted a prospective, randomized, double-blind pilot study of oral ciprofloxacin (500 mg twice daily) versus cefuroxime axetil (250 mg twice daily) for 2 to 3 weeks in the treatment of adult patients with a clinical diagnosis of acute bacterial maxillary sinus infections or acute exacerbation of chronic bacterial sinusitis." | 5.08 | Ciprofloxacin versus cefuroxime axetil in the treatment of adult patients with acute bacterial sinusitis. ( Echols, RM; Heyd, A; Klein, GL; Whalen, E, 1998) |
| "A total of 251 adults with chronic sinusitis were enrolled into this prospective multicentre, double-blind, double-placebo comparison of ciprofloxacin (500 mg twice daily) with amoxycillin/clavulanic acid (500 mg three times daily)." | 5.07 | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| "80 adult outpatients suffering from otitis media, sinusitis (maxillaris or frontalis) or peritonsillitis were treated with 500 mg ciprofloxacin b." | 5.06 | Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V--a comparison. ( Falser, N; Mittermayer, H; Weuta, H, 1988) |
| "Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy)." | 4.85 | Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. ( Agbaht, K; Bayraktar, M; Bitik, B; Piskinpasa, S; Topeli, A, 2009) |
| " We describe a case of acute-onset peripheral neuropathy associated with ciprofloxacin in a 13-year-old boy who was characterized by severe dysesthesia and erythema of both hands and feet, but which resolved promptly after ceasing the antibiotic." | 4.12 | Ciprofloxacin-associated Peripheral Neuropathy in a Child: A Case Report and Review of the Literature. ( Carvalho de Almeida, C; Grimwood, K; Moloney, S; Morley, C, 2022) |
| "We recently developed a ciprofloxacin and azithromycin sinus stent (CASS) to target recalcitrant infections in chronic rhinosinusitis (CRS)." | 4.02 | Azithromycin and ciprofloxacin inhibit interleukin-8 secretion without disrupting human sinonasal epithelial integrity in vitro. ( Ayinala, S; Cho, DY; Grayson, JW; Lim, DJ; Skinner, D; Thompson, HM; Walz, CR; Woodworth, BA; Zhang, S, 2021) |
| "To test whether intranasal ciprofloxacin/dexamethasone or dexamethasone alone affects the course of acute bacterial rhinosinusitis in mice." | 3.74 | Effect of topical ciprofloxacin/dexamethasone or dexamethasone alone on acute Streptococcus pneumoniae rhinosinusitis in mice. ( Baroody, F; Markaryan, A; Naclerio, R; Sahin-Yilmaz, A; Thompson, K; Wall, GM, 2008) |
| " Ten adverse events were observed in seven patients and in four (7%) of these treatment had to be withdrawn." | 2.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "Ciprofloxacin resistance has increased, while Ceftazidime susceptibility is unchanged (> 90 %)." | 1.31 | [Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections]. ( Elies, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Morley, C | 1 |
| Carvalho de Almeida, C | 1 |
| Moloney, S | 1 |
| Grimwood, K | 1 |
| Orabi, NA | 3 |
| Behnke, J | 3 |
| Reyes, C | 3 |
| Ramadan, HH | 3 |
| Makary, CA | 3 |
| Lim, DJ | 3 |
| McCormick, J | 1 |
| Skinner, D | 3 |
| Zhang, S | 2 |
| Elder, JB | 1 |
| McLemore, JG | 1 |
| Allen, M | 1 |
| West, JM | 1 |
| Grayson, JW | 2 |
| Rowe, SM | 1 |
| Woodworth, BA | 3 |
| Cho, DY | 3 |
| Thompson, HM | 1 |
| Walz, CR | 1 |
| Ayinala, S | 1 |
| Mackey, C | 1 |
| Weeks, C | 1 |
| Gill, GS | 1 |
| Hergenrother, RW | 1 |
| Swords, WE | 1 |
| Agbaht, K | 1 |
| Bitik, B | 1 |
| Piskinpasa, S | 1 |
| Bayraktar, M | 1 |
| Topeli, A | 1 |
| Guss, J | 1 |
| Abuzeid, WM | 1 |
| Doghramji, L | 1 |
| Edelstein, PH | 1 |
| Chiu, AG | 1 |
| Sahin-Yilmaz, A | 1 |
| Baroody, F | 1 |
| Markaryan, A | 1 |
| Thompson, K | 1 |
| Wall, GM | 1 |
| Naclerio, R | 1 |
| Fombeur, JP | 2 |
| Barrault, S | 1 |
| Koubbi, G | 1 |
| Laurier, JN | 1 |
| Ebbo, D | 1 |
| Lecomte, F | 1 |
| Sorrel, N | 1 |
| Dobler, S | 1 |
| Legent, F | 1 |
| Bordure, P | 1 |
| Beauvillain, C | 1 |
| Berche, P | 2 |
| Gaillot, O | 1 |
| Klein, GL | 1 |
| Whalen, E | 1 |
| Echols, RM | 1 |
| Heyd, A | 1 |
| Weber, P | 1 |
| Lelièvre, G | 1 |
| Elies, W | 1 |
| Falser, N | 1 |
| Mittermayer, H | 1 |
| Weuta, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciprofloxacin and Sinusitis
| Article | Year |
|---|---|
Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review.
Topics: Anti-Infective Agents; Ciprofloxacin; Electroencephalography; Female; Humans; Risk Factors; Seizures | 2009 |
4 trials available for ciprofloxacin and Sinusitis
| Article | Year |
|---|---|
Study of the efficacy and safety of ciprofloxacin in the treatment of chronic sinusitis.
Topics: Adult; Chronic Disease; Ciprofloxacin; Female; Gram-Negative Bacterial Infections; Gram-Positive Bac | 1994 |
A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis.
Topics: Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; | 1994 |
Ciprofloxacin versus cefuroxime axetil in the treatment of adult patients with acute bacterial sinusitis.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Anti-Infective Agents; Cefuroxime; Cephalosporins; | 1998 |
Antibacterial treatment of otitis and sinusitis with ciprofloxacin and penicillin V--a comparison.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Frontal Sinus; Humans; Maxilla | 1988 |
12 other studies available for ciprofloxacin and Sinusitis
| Article | Year |
|---|---|
Ciprofloxacin-associated Peripheral Neuropathy in a Child: A Case Report and Review of the Literature.
Topics: Adolescent; Anti-Bacterial Agents; Ciprofloxacin; Erythema; Foot; Hand; Humans; Male; Osteomyelitis; | 2022 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Effect of absorbable nasal packing saturated with ciprofloxacin and dexamethasone following endoscopic sinus surgery: A prospective cohort study.
Topics: Chronic Disease; Ciprofloxacin; Dexamethasone; Endoscopy; Epistaxis; Humans; Paranasal Sinuses; Pros | 2023 |
Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis.
Topics: Aminophenols; Animals; Chronic Disease; Ciprofloxacin; Maxillary Sinus; Pseudomonas; Pseudomonas Inf | 2020 |
Azithromycin and ciprofloxacin inhibit interleukin-8 secretion without disrupting human sinonasal epithelial integrity in vitro.
Topics: Azithromycin; Ciprofloxacin; Epithelial Cells; Humans; Interleukin-8; Paranasal Sinuses; Sinusitis | 2021 |
Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Cells, Cultured; Ciprofloxacin; Disease Mo | 2018 |
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluo | 2009 |
Effect of topical ciprofloxacin/dexamethasone or dexamethasone alone on acute Streptococcus pneumoniae rhinosinusitis in mice.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Dex | 2008 |
In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
Topics: Adult; Anti-Infective Agents; Bacteria; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; | 1995 |
[The role of ciprofloxacin in the management of chronic sinusitis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Humans; Sinusitis | 1998 |
[Bacteriology in community-acquired respiratory pathology].
Topics: Acute Disease; Ambulatory Care; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprof | 1998 |
[Chronic ORL infections of the adult in the community. Role of ciprofloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Chronic Disease; Ciprofloxacin; Humans; Otitis Media; S | 2001 |
[Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections].
Topics: Ceftazidime; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Dose-Response Relationship, D | 2002 |